(EMAILWIRE.COM, July 14, 2018 ) According to a new market research report "Plasma Therapy Market by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), End User, Region - Global Forecast to 2021" published by MarketsandMarkets, The global market is expected to grow from USD 135.6 Million in 2016 to USD 297.6 Million by 2021, at a CAGR of 14.0% from 2016 to 2021.

Browse 141 market data Tables and 98 Figures spread through 210 Pages and in-depth TOC on "Plasma Therapy Market".

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=186196333

On the basis of type, the plasma therapy market is segmented into pure PRP, leucocyte-rich PRP, platelet-rich fibrin (PRF), and leukocyte-rich fibrin (L-PRF). The pure PRP segment is estimated to account for the largest share of the global market in 2016. One of the most significant factors driving the growth of this market includes the effective results of pure PRP therapy. However, lack of reimbursement policies and varying prices of plasma therapy are hindering the growth of the market.

On the basis of source, the market is segmented into autologous and allogenic. The autologous segment is estimated to account for the largest share of the global market in 2016. Awareness of plasma therapy and its acceptance as a suitable remedy for healing of bones and other tissues are driving the growth of the autologous source segment of the market.

Based on application, the plasma therapy market is segmented into orthopedics, dermatology, dental, cardiac muscle injury, nerve injury, and others. The orthopedic segment is further segmented into arthritis, chronic tendinitis, and bone repair & regeneration. Similarly, the dermatology segment is further segmented into androgenic alopecia and plastic surgery. The dermatology segment is expected to grow at the highest CAGR from 2016 to 2021, owing to the increasing number of dermatological disorders.

On the basis of end user, the market is classified into hospitals & clinics and research institutions. The hospitals & clinics segment is estimated to account for the largest share of the global market in 2016. This large share is mainly attributed to rise in healthcare expenditure and increase in the use of PRP products in hospitals.

Geographically, the market is led by North America, followed by Europe, Asia-Pacific, and rest of the world (RoW). Growth in the global market is primarily driven by the increase in aging population and rise in the number of orthopedic disorders.

Major players in the plasma therapy market include BioLife Plasma Services (U.S.), Cambryn Biologics LLC (U.S.), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB (France), Bio Products Laboratory Ltd. (U.K.), China Biologic Products, Inc. (China), and Octapharma (Switzerland).

Speak To Analyst: https://www.marketsandmarkets.com/speaktoanalyst.asp?id=186196333